A Phase II Study of Eribulin in Recurrent or Refractory Osteosarcoma: a report from the Children’s Oncology Group

BACKGROUND: Patients with recurrent or refractory osteosarcoma have a poor prognosis with less than 30% surviving 2 years. Eribulin is a synthetic analog of halichondrin B, has a novel mechanism of action when compared to other microtubule inhibitors and may have anti-tumor activity in osteosarcoma....

全面介紹

Na minha lista:
書目詳細資料
發表在:Pediatr Blood Cancer
Main Authors: Isakoff, Michael S., Goldsby, Robert, Villaluna, Doojduen, Krailo, Mark D., Hingorani, Pooja, Collier, Anderson, Morris, Carol D., Kolb, E. Anders, Doski, John J., Womer, Richard B., Gorlick, Richard, Janeway, Katherine A.
格式: Artigo
語言:Inglês
出版: 2018
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6501793/
https://ncbi.nlm.nih.gov/pubmed/30378256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.27524
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍